Literature DB >> 11756599

Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study.

M C Carlson1, P P Zandi, B L Plassman, J T Tschanz, K A Welsh-Bohmer, D C Steffens, L A Bastian, K M Mehta, J C Breitner.   

Abstract

OBJECTIVE: To examine the association between postmenopausal hormone replacement therapy (HRT) and the trajectory of global cognitive change with age.
METHODS: The Modified Mini-Mental State Examination (MMSE) was administered to a population sample of 2,073 nondemented, community-dwelling female residents of Cache County, UT, aged 65 and older. Current and past HRT and other medications at a baseline interview and at follow-up 3 years later were assessed. Between interviews, a telephone Women's Health Questionnaire was administered to assess initial exposure, duration, and recency of HRT. Generalized estimating equation marginal models were used to evaluate the cross-sectional and longitudinal relations of HRT and modified MMSE score. Also assessed were effects with multivitamins and calcium supplements as exposures likely to reflect a "healthy lifestyle" among HRT users. Model covariates included the presence of APOE epsilon4 alleles, age, education, concurrent depression, several chronic diseases, and self-perceived general health.
RESULTS: Age, lower education, depression, and APOE epsilon4 were all associated with lower baseline modified MMSE scores. With these covariates in the model, lifetime HRT use was associated with better baseline modified MMSE scores and a slower rate of decline. Stratification by APOE genotype did not alter these effects. Apparent benefits with HRT were attenuated but remained significant after elimination of scores from participants with incident dementia. A significant interaction between age and HRT indicated the strongest effects in women aged 85 and older. Measures of age at initial use of HRT, duration, and recency of exposure did not improve the models. No effects were seen with the "healthy lifestyle" control exposures.
CONCLUSIONS: In a population cohort of older women, lifetime HRT exposure was associated with improved global cognition and attenuated decline over a 3-year interval. Improvements were greatest in the oldest old.

Entities:  

Mesh:

Year:  2001        PMID: 11756599     DOI: 10.1212/wnl.57.12.2210

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

Review 1.  Prevention of Alzheimer's disease: where we stand.

Authors:  Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

2.  Effects of synaptic plasticity regulated by 17beta-estradiol on learning and memory in rats with Alzheimer's disease.

Authors:  Xiu-Li Shang; Jiu-Han Zhao; Yun-Peng Cao; Yi-Xue Xue
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

Review 3.  Protective actions of sex steroid hormones in Alzheimer's disease.

Authors:  Christian J Pike; Jenna C Carroll; Emily R Rosario; Anna M Barron
Journal:  Front Neuroendocrinol       Date:  2009-05-07       Impact factor: 8.606

Review 4.  Cognitive changes after menopause: influence of estrogen.

Authors:  Victor W Henderson
Journal:  Clin Obstet Gynecol       Date:  2008-09       Impact factor: 2.190

5.  Continuously delivered ovarian steroids do not alter dendritic spine density or morphology in macaque dorsolateral prefrontal cortical neurons.

Authors:  M E Young; D T Ohm; W G M Janssen; N A Gee; B L Lasley; J H Morrison
Journal:  Neuroscience       Date:  2013-10-10       Impact factor: 3.590

6.  II. Cognitive performance of middle-aged female rats is influenced by capacity to metabolize progesterone in the prefrontal cortex and hippocampus.

Authors:  Jason J Paris; Alicia A Walf; Cheryl A Frye
Journal:  Brain Res       Date:  2010-10-31       Impact factor: 3.252

Review 7.  Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease.

Authors:  Jacqueline O'Brien; John W Jackson; Francine Grodstein; Deborah Blacker; Jennifer Weuve
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

Review 8.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

9.  A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics.

Authors:  Mary Sano; Diane Jacobs; Howard Andrews; Karen Bell; Neill Graff-Radford; John Lucas; Peter Rabins; Karen Bolla; Wei-Yan Tsai; Peter Cross; Karen Andrews; Rosann Costa
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

10.  Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study".

Authors:  Sanjay Asthana; Roberta Diaz Brinton; Victor W Henderson; Bruce S McEwen; John H Morrison; Peter J Schmidt
Journal:  Age (Dordr)       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.